Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting

Chimeric antigen receptor anti-CD19 (CAR19)-T cell immunotherapy-induced clinical remissions in CD19(+) B cell lymphomas are often short lived. We tested whether CAR19-engineering of the CD1d-restricted invariant natural killer T (iNKT) cells would result in enhanced anti-lymphoma activity. CAR19-iN...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell
Main Authors: Rotolo, Antonia, Caputo, Valentina S., Holubova, Monika, Baxan, Nicoleta, Dubois, Olivier, Chaudhry, Mohammed Suhail, Xiao, Xiaolin, Goudevenou, Katerina, Pitcher, David S., Petevi, Kyriaki, Kachramanoglou, Carolina, Iles, Sandra, Naresh, Kikkeri, Maher, John, Karadimitris, Anastasios
Formato: Artigo
Idioma:Inglês
Publicado em: Cell Press 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6179961/
https://ncbi.nlm.nih.gov/pubmed/30300581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2018.08.017
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados